title: [Effect of acipimox on diabetes mellitus-associated hyperlipoproteinemia].
abstract: The authors give summary on the pathogenesis of hyperlipoproteinaemia in patients with diabetes mellitus. They investigated the effects of acid nicotinic derivate acipimox on lipid metabolism in these patients. They treated with acipimox 15 patients who suffered from non-insulin-dependent diabetes mellitus, as well as II/B, IV type hyperlipoproteinaemia by Fredrickson. They investigated the effect of acipimox on the lipoprotein content and quality in the sera and uric acid and carbohydrate metabolism. The authors found decreased cholesterol, triglyceride, apolipoprotein-B, glycosilated haemoglobin, glucose and uric acid levels in the sera and they found that the atherogenic index decreased too. During the treatment they could not recognise a change in the low-density lipoprotein level of the sera while the high density lipoprotein and apo-A1 level increased.
authors.affiliation: Debreceni Orvostudományi Egyetem, Belgyógyászati Klinika.
authors.forename: G
authors.initials: G
authors.lastname: Paragh
authors.forename: Z
authors.initials: Z
authors.lastname: Balogh
authors.forename: J
authors.initials: J
authors.lastname: Boda
authors.forename: A
authors.initials: A
authors.lastname: Mohácsi
authors.forename: A
authors.initials: A
authors.lastname: Juhász
authors.forename: A
authors.initials: A
authors.lastname: Leövey
mesh_terms: D000328:Adult; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications; D005260:Female; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood / Q000188:drug therapy / Q000209:etiology*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011719:Pyrazines / Q000627:therapeutic use*
chemical_list: D000960:Hypolipidemic Agents; D011719:Pyrazines; C027696:acipimox